{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:55:23Z","timestamp":1790798123179,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s41669-021-00293-4","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T13:02:43Z","timestamp":1636808563000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6555-6083","authenticated-orcid":false,"given":"Imad","family":"Treish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2952-9103","authenticated-orcid":false,"given":"Abeer","family":"Al Rabayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Jaddoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-3480","authenticated-orcid":false,"given":"Haitham","family":"Tuffaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"293_CR1","unstructured":"American Cancer Society. Global Cancer Facts & Figures 4th Edition. Published online 2018. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/global-cancer-facts-and-figures\/global-cancer-facts-and-figures-4th-edition.pdf. Accessed 30 May 2021."},{"key":"293_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/phar.1867","volume":"37","author":"AE Glode","year":"2017","unstructured":"Glode AE, May MB. Rising cost of cancer pharmaceuticals: cost issues and interventions to control costs. Pharmacotherapy. 2017;37:85\u201393.","journal-title":"Pharmacotherapy"},{"key":"293_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/bjc.2015.56","volume":"112","author":"P Savage","year":"2015","unstructured":"Savage P, Mahmoud S. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010\u20132014. Br J Cancer. 2015;112:1037\u201341.","journal-title":"Br J Cancer"},{"key":"293_CR4","doi-asserted-by":"publisher","DOI":"10.13140\/RG.2.2.31627.92961","author":"OF Nimri","year":"2020","unstructured":"Nimri OF, Arqoub K. Statistical Digest Jordan Cancer Registry (JCR) Cancer Incidence in Jordan-2016 Non-Communicable Diseases Directorate-MOH. Publ Online. 2020. https:\/\/doi.org\/10.13140\/RG.2.2.31627.92961.","journal-title":"Publ Online"},{"key":"293_CR5","unstructured":"Jordan Statistical Yearbook 2017\u2014Department of Statistics. http:\/\/dosweb.dos.gov.jo\/products\/statistical_yearbook2017\/. Accessed 9 June 2021."},{"key":"293_CR6","unstructured":"Life expectancy at birth, total (years) - Jordan. https:\/\/data.worldbank.org\/indicator\/SP.DYN.LE00.IN?locations=JO&view=chart. Accessed 1 Mar 2021."},{"key":"293_CR7","unstructured":"World Bank. World Bank. GNI per capita, Atlas method (current US$)\u2014Jordan. https:\/\/data.worldbank.org\/indicator\/NY.GNP.PCAP.CD?end=2018&locations=JO&start=2007&view=chart. Accessed 1 May 2020."},{"key":"293_CR8","unstructured":"Jordan High Health Council. Jordan National Health Accounts for 2016-2017 Fiscal Years. Published online 2019. http:\/\/www.hhc.gov.jo\/uploadedimages\/%D9%85%D8%A4%D8%B4%D8%B1%D8%A7%D8%AA%20%D8%A7%D9%84%D8%A7%D9%86%D9%81%D8%A7%D9%82%20%D8%A7%D9%84%D8%B5%D8%AD%D9%8A%20.pdf. Accessed 30 May 2021."},{"key":"293_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.hemonc.2015.02.001","volume":"8","author":"H Abdel-Razeq","year":"2015","unstructured":"Abdel-Razeq H, Attiga F, Mansour A. Cancer care in Jordan. Hematol Oncol Stem Cell Ther. 2015;8:64\u201370.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"293_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1744-8603-3-11","volume":"3","author":"JL Moe","year":"2007","unstructured":"Moe JL, Pappas G, Murray A. Transformational leadership, transnational culture and political competence in globalizing health care services: a case study of Jordan\u2019s King Hussein Cancer Center. Global Health. 2007;3:11.","journal-title":"Global Health"},{"key":"293_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jval.2012.04.006","volume":"15","author":"R Lafi","year":"2012","unstructured":"Lafi R, Robinson S, Williams I. economic evaluation and the Jordan rational drug list: an exploratory study of national-level priority setting. Value in Health. 2012;15:771\u20136.","journal-title":"Value in Health."},{"key":"293_CR12","unstructured":"Jordan Food and Drug Administration; Medication Pricing Instruction in Jordan. http:\/\/jfda.jo\/EchoBusV3.0\/SystemAssets\/PDF\/AR\/LawsAndRegulation\/Drug\/PricingSection. Accessed 1 Mar 2021."},{"key":"293_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jval.2015.11.007","volume":"19","author":"EA Hammad","year":"2016","unstructured":"Hammad EA. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan. Value in Health. 2016;19:233\u20138.","journal-title":"Value in Health."},{"key":"293_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost\u2013effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118\u201324.","journal-title":"Bull World Health Organ"},{"key":"293_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14737167.2018.1443810","volume":"18","author":"AS Santos","year":"2018","unstructured":"Santos AS, Guerra-Junior AA, Godman B, Morton A, Ruas CM. Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert Rev Pharmacoecon Outcomes Res. 2018;18:277\u201388.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"293_CR16","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"293_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1098-3015(10)67137-9","volume":"11","author":"M Jabr","year":"2008","unstructured":"Jabr M, Treish I. PCASE1 establishment of a cost-effectiveness (CE) threshold at King Hussein Cancer Center: imatinib in chronic myelogenous leukemia (CML). Value in Health. 2008;11:657.","journal-title":"Value in Health."},{"key":"293_CR18","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1002\/cncr.20694","volume":"101","author":"SD Reed","year":"2004","unstructured":"Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-? plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101:2574\u201383.","journal-title":"Cancer"},{"issue":"1","key":"293_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1017\/S0266462321000246","volume":"37","author":"A Al-Rabayah","year":"2021","unstructured":"Al-Rabayah A, Jaddoua S. Establishment and implementation of hospital-based health technology assessment at King Hussein Cancer Center: Can our model be an example? Int J Technol Assess Health Care. 2021;37(1):55. https:\/\/doi.org\/10.1017\/S0266462321000246.","journal-title":"Int J Technol Assess Health Care"},{"key":"293_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. N Engl J Med [Internet]. 2014;371:796\u20137.","journal-title":"N Engl J Med [Internet]."},{"key":"293_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"293_CR22","doi-asserted-by":"crossref","unstructured":"Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.","DOI":"10.1155\/2014\/357027"},{"key":"293_CR23","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1056\/NEJMe030009","volume":"348","author":"K Peggs","year":"2003","unstructured":"Peggs K, Mackinnon S. Imatinib Mesylate\u2014the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348:1048\u201350.","journal-title":"N Engl J Med"},{"key":"293_CR24","unstructured":"Timmins, N, Rawlins, M, Appleby, J (eds) A terrible beauty: a short history of NICE, pp.\u00a0154\u2013169. http:\/\/www.idsihealth.org\/wp-content\/uploads\/2016\/02\/A-TERRIBLE-BEAUTY_resize.pdf. Accessed 8 Apr 2020."},{"issue":"14","key":"293_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","volume":"19","author":"K Claxton","year":"2015","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1\u201350326.","journal-title":"Health Technol Assess"},{"key":"293_CR26","unstructured":"Dillon SA. Carrying NICE over the threshold. NICE. https:\/\/www.nice.org.uk\/news\/blog\/carrying-nice-over-the-threshold. Accessed Mar 20 2021"},{"issue":"8","key":"293_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929\u201335.","journal-title":"Value Health."},{"issue":"1","key":"293_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s41669-018-0088-x","volume":"3","author":"F Maraiki","year":"2019","unstructured":"Maraiki F, Byrnes J, Tuffaha H, Hinder M. International HTA experience with targeted therapy approvals for lung cancer. Pharmacoecon Open. 2019;3(1):103\u201317.","journal-title":"Pharmacoecon Open."},{"issue":"5","key":"293_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40273-018-0633-6","volume":"36","author":"HW Tuffaha","year":"2018","unstructured":"Tuffaha HW, Scuffham PA. The Australian managed entry scheme: are we getting it right? Pharmacoeconomics. 2018;36(5):555\u201365.","journal-title":"Pharmacoeconomics"},{"key":"293_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jval.2017.12.010","volume":"21","author":"CE Phelps","year":"2018","unstructured":"Phelps CE, Lakdawalla DN, Basu A, Drummond MF, Towse A, Danzon PM. Approaches to aggregation and decision making\u2014a health economics approach: an ISPOR Special Task Force Report. Value Health. 2018;21:146\u201354.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-021-00293-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T17:45:07Z","timestamp":1645551907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-021-00293-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s41669-021-00293-4","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"30 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Haitham Tuffaha is funded by an NHMRC Early Career Fellowship (GNT1121232).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have nothing to disclose in terms of conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"King Hussein Cancer Centre Institutional Review Board.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IT conceptualized and drafted the manuscript. All authors critically revised the manuscript and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}